Pyrosequencing™-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance

Pharmacogenomics

Volumn 7, Issue 7, 2006, Pages 995-1002

  Rohrbacher, Maren ^a   Kirchhof, Anja ^a   Geisslinger, Gerd ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

7; CYP2B6*4,*5,*6,; Drug metabolism; Pharmacogenetics; Pyrosequencing technique; Screening assays; Single nucleotide polymorphism

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 2B6; CYTOSINE; DNA; EFAVIRENZ; GUANINE; THYMINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; N DEMETHYLASE; OXAZINE DERIVATIVE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ACCURACY; ADULT; ARTICLE; ASSAY; CATALYSIS; CAUCASIAN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; EXON; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PROTEIN EXPRESSION; RELIABILITY; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM; VOLUNTEER; ALLELE; DNA SEQUENCE; ETHNIC GROUP; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INSTRUMENTATION; MIDDLE AGED; MOLECULAR GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ALLELES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; ETHNIC GROUPS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OXAZINES; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 33750454425     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.7.995     Document Type: Article

References (37)

1. Nolan D, Phillips E, Mallal S: Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin. Infect. Dis. 42, 408-410 (2006).
2. Rotger M, Colombo S, Forcer H et al: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15, 1-5 (2005).
3. Haas DW, Ribaudo HJ, Kim RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18, 2391-2400 (2004).
4. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287-300 (2003).
5. Haas DW, Smeaton LM, Shafer RW et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192, 1931-1942 (2005).
6. Tsuchiya K, Gatanaga H, Tachikawa N et al.: Homozygous CYP2B6 *6(Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Common. 319, 1322-1326 (2004).
7. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I. Gonzalez-Lahoz J, Soriano V: Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV infected subjects. Clin. Infect. Dis. 40, 1358-1361 (2005).
8. Ribaudo HJ, Haas DW, Tierney C et al.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Infect. Dis. 42, 401-407 (2006).
9. Hasse B, Gunthard HF, Bleiber G, Krause M: Efavirenz intoxication due to slow hepatic metabolism. Clin. Infect. Dis. 40, E22-E23 (2005).
10. Hoffman SM, Nelson DR, Keeney DS: Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11, 687-98 (2001).
11. Lang T, Klein K, Fischer J et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11, 399-415 (2001).
12. Lamba V. Lamba J, Yasuda K et al.: Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307, 906-22 (2003).
13. Lang T, Klein K, Richter T et al.: Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther. 311, 34-43 (2004).
14. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL et al.: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14, 225-238 (2004).
15. Zukunft J, Lang T, Richter T et al.: A natural CYP2B6TATA box polymorphism (-82T → C) leading to enhanced transcription and relocation of the transcriptional start site. Mol. Pharmacol. 67, 1772-1782 (2005).
16. Klein K, Lang T, Saussele T et al.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15, 861-873 (2005).
17. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ: Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25, 985-993 (1997).
18. Hesse LM, Venkatakrishnan K, Court MH et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion potential drug interactions with other antidepressants. Drug Metab. Dispos. 28, 1176-1183 (2000).
19. Faucette SR, Hawke RL, Lecluyse EL et al.: Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28, 1222-1230 (2000).
20. Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW: Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab. Dispos. 27, 533-541 (1999).
21. Chang TK, Weber GF, Crespi CL, Waxman DJ: Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53, 5629-37 (1993).
22. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ: Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P450. Drug Metab. Dispos. 27, 1488-1495 (1999).
23. Bumpus NN, Sridar C, Kent UM, Hollenberg PF: The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P4502B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab. Dispos. 33, 795-802 (2005).
24. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P: Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem. 242, 84-89 (1996).
25. Gaut BS, Long AD: The lowdown on linkage disequilibrium. Plant Cell 15, 1502-1506 (2003).
26. Jacob RM, Johnstone EC, Neville MJ, Walton RT: Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem. 50, 1372-1377 (2004).
27. Alderborn A, Kristofferson A, Hammerling U: Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing Genome Res. 10, 1249-1258 (2000).
28. Darimont J, Grosch S, Skarke C, Geisslinger G, Lotsch J: Comparison of two screening methods for in-house genotyping in clinical pharmacology units. Int. J. Clin. Pharmacol. Ther. 43, 17-22 (2005).
29. Xie HJ, Yasar U, Lundgren S et al.: Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 3, 53-61 (2003).
30. Jinno H, Tanaka-Kagawa T, Ohno A et al.: Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31, 398-403 (2003).
31. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T: A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 281, 1256-1260 (2001).
32. Burger D, van der Heiden I, la Porte C et al.: Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. 61, 148-154 (2006).
33. Wang J, Sonnerborg A, Rane A et al.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16, 191-198 (2006).
34. Saitoh A, Singh KK, Powell CA et al.: An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19, 371-380 (2005).
35. Takada K, Arefayene M, Desta Z et al.: Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum. 50, 2202-2210 (2004).
36. Lerman C, Shields PG, Wileyto EP et al.: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12, 627-634 (2002).
37. Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Rendon A, Soriano V: Pharmacogenetics in HIV therapy. AIDS Rev 7, 103-112 (2005).